Outset Medical (TASE:BLWV) Inc. (OM) stock has reached a new 52-week low, touching down at $0.43, marking a stark decline from its 52-week high of $5.22. This latest price level reflects a significant downturn for the company, with a market capitalization now at just $22.55 million. The stock has seen its value plummet by over 71% in the past year, with particularly concerning metrics showing a nearly 48% decline year-to-date. Investors have been closely monitoring Outset Medical’s performance, as the company grapples with market pressures and investor sentiment. While the company maintains strong liquidity with a current ratio of 5.69, it faces significant challenges with negative EBITDA of -$102 million. According to InvestingPro analysis, the stock appears undervalued at current levels, with additional insights available through the comprehensive Pro Research Report, which provides deep-dive analysis of this and 1,400+ other US stocks.
In other recent news, Outset Medical Inc. reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of -$0.37, which exceeded analyst expectations of -$0.43. The company’s revenue for the quarter was $29.5 million, slightly above projections, indicating a positive financial performance. Additionally, Outset Medical announced a reverse stock split at a ratio of one-for-fifteen, set to take effect on March 20, 2025, which aims to consolidate the number of shares and potentially attract new investors. In another development, the company corrected a clerical error in its preferred stock documentation, which involved a mathematical formula adjustment. This correction followed a stockholder-approved conversion of 842,753 shares of Series A Preferred Stock into 210,688,250 shares of common stock. Furthermore, the firm has projected revenue between $115 million and $125 million for 2025, with plans to grow its installed base and recurring revenue by 10%. Outset Medical’s operational improvements have included significant debt reduction and increased recurring revenue, as highlighted by their recent earnings call. Lastly, the company has secured $172.7 million in equity financing, which is expected to support its path to cash flow breakeven.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.